Voyager Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Voyager Therapeutics est Al Sandrock, nommé en Mar2022, a un mandat de 2.67 ans. La rémunération annuelle totale est $ 3.17M, composée du salaire de 19.7% et des bonus 80.3%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de € 338.59K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.2 ans et 4.8 ans.

Informations clés

Al Sandrock

Directeur général

US$3.2m

Rémunération totale

Pourcentage du salaire du PDG	19.7%
Durée du mandat du directeur général	2.7yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	2.2yrs
Durée moyenne du mandat des membres du conseil d'administration	4.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Al Sandrock a-t-elle évolué par rapport aux bénéfices de Voyager Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$26m
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$3m	US$624k	US$132m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$96m
Mar 31 2023	n/a	n/a	US$99m
Dec 31 2022	US$7m	US$525k	-US$46m

Rémunération vs marché: La rémunération totale de Al ($USD 3.17M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.03M ).

Rémunération et revenus: La rémunération de Al a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Al Sandrock (66 yo)

2.7yrs

Titularisation

US$3,172,433

Compensation

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He served as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Alfred Sandrock	President	2.7yrs	US$3.17m	0.12% € 338.6k
Robin Swartz	Chief Business Officer & COO	no data	US$1.38m	0.062% € 181.4k
Jacquelyn Sandell	Chief Legal Officer	1.3yrs	US$1.91m	0.026% € 77.2k
Krystof Bankiewicz	Founder	no data	pas de données	pas de données
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Mark Kay	Founder	no data	pas de données	pas de données
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Nathan Jorgensen	Chief Financial Officer	less than a year	pas de données	pas de données
Todd Carter	Chief Scientific Officer	2.2yrs	pas de données	0.16% € 472.1k
Michelle Smith	Chief Human Resources Officer	4.2yrs	pas de données	pas de données
Trista Morrison	Chief Corporate Affairs Officer & Chief of Staff to the CEO	2.8yrs	pas de données	pas de données
Toby Ferguson	Chief Medical Officer	less than a year	pas de données	pas de données

2.2yrs

Durée moyenne de l'emploi

53.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de VT6 est considérée comme expérimentée (ancienneté moyenne 2.2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Alfred Sandrock	President	2.8yrs	US$3.17m	0.12% € 338.6k
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Dinah Sah	Consultant & Member of Scientific Advisory Board	5.4yrs	US$1.81m	pas de données
James Arthur Geraghty	Independent Director	10.8yrs	US$263.78k	0.10% € 294.1k
Glenn Pierce	Independent Director	7.8yrs	US$248.78k	0.040% € 117.4k
Steven Hyman	Independent Director	9.2yrs	US$255.78k	0% € 0
Michael Higgins	Independent Chairman of the Board	9.3yrs	US$281.28k	0.057% € 168.7k
Catherine Mackey	Independent Director	2.3yrs	US$250.78k	0% € 0
Jude Onyia	Director	1.8yrs	US$452.32k	0.0053% € 15.7k
Grace Colon	Independent Director	1.8yrs	US$432.23k	0% € 0
Nancy Vitale	Independent Director	4.2yrs	US$255.28k	0% € 0

4.8yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de VT6 sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).

Voyager Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold €111k worth of stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

President recently sold €90k worth of stock

Recent updates

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023)

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 23%

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023)

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023)

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

President recently sold €90k worth of stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New major risk - Shareholder dilution

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Investor sentiment improves as stock rises 26%

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022)

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold €91k worth of stock

Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022)

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment deteriorates as stock falls 16%

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 19%

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022)

President recently sold €54k worth of stock

Chief Operating Officer recently sold €120k worth of stock

Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021)

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021)

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021)

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. Announces Executive Appointments

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index